表紙
市場調查報告書

抗癌劑的全球市場的預測:競爭、預測、機會 - 各醫藥品類型、治療方法、藥物療法、給藥途徑、性別、疾病、流通管道、地區

Global Oncology Drugs Market, By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), Therapy, Drug Therapy, Route of Administration, Gender, Cancer Type, Distribution Channel, Region, Competition, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 932041
出版日期 內容資訊 英文 117 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

抗癌劑的全球市場的預測:競爭、預測、機會 - 各醫藥品類型、治療方法、藥物療法、給藥途徑、性別、疾病、流通管道、地區 Global Oncology Drugs Market, By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), Therapy, Drug Therapy, Route of Administration, Gender, Cancer Type, Distribution Channel, Region, Competition, Forecast & Opportunities, 2025
出版日期: 2020年04月01日內容資訊: 英文 117 Pages
簡介

全球抗癌劑市場,以全球癌症的盛行率上升為背景,在預測期間內急速成長。由於老年人口的全球性增加,及法規當局的產品核可數量的增加,新藥開發的研究開發擴大,醫療費的增加,癌症治療用生物相似藥的登場,製藥企業的共同研究等促進該市場成長。

本報告提供全球抗癌劑市場調查,市場概要,各醫藥品類型、治療方法、藥物療法、給藥途徑、性別、疾病、流通管道、地區的市場規模的變化與預測,市場成長要素及課題,市場機會,市場佔有率,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 客戶的迴響

第5章 全球抗癌劑市場概要

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
  • 各醫藥品類型
    • 細胞毒性藥
    • 分子標靶治療藥
    • 荷爾蒙劑
  • 各治療法
    • 化療
    • 分子標靶治療
    • 免疫療法
    • 荷爾蒙療法
    • 其他
  • 各藥物療法
    • 佐劑療法
    • 新佐劑療法
    • 同時聯合治療
  • 各給藥途徑
    • 口服給藥
    • 經靜脈給藥
    • 皮下注射治療
    • 其他
  • 性別
    • 男性
    • 女性
  • 各疾病類型
    • 肺癌症
    • 胃癌
    • 大腸癌症
    • 乳癌
    • 前列腺癌症
    • 肝癌症
    • 食道癌症
    • 子宮頸癌症
    • 腎癌症
    • 膀胱癌
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
    • 政府醫院
  • 各企業
  • 各地區
  • 市場魅力指標

第6章 亞太地區的抗癌劑市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品類型
    • 各治療法
    • 各藥物療法
    • 各給藥途徑
    • 性別
    • 各疾病
    • 各流通管道
    • 各國
  • 市場分析:各國
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 澳洲

第7章 歐洲的抗癌劑市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品類型
    • 各治療法
    • 各藥物療法
    • 各給藥途徑
    • 性別
    • 各疾病
    • 各流通管道
    • 各國
  • 市場分析:各國
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章 北美的抗癌劑市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品類型
    • 各治療法
    • 各藥物療法
    • 各給藥途徑
    • 性別
    • 各疾病
    • 各流通管道
    • 各國
  • 市場分析:各國
    • 美國
    • 墨西哥
    • 加拿大

第9章 南美的抗癌劑市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 醫藥品各類型
    • 各治療法
    • 各藥物療法
    • 各給藥途徑
    • 性別
    • 各疾病
    • 各流通管道
    • 各國
  • 市場分析:各國
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 中東、非洲的抗癌劑市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各醫藥品類型
    • 各治療法
    • 各藥物療法
    • 各給藥途徑
    • 性別
    • 各疾病
    • 各流通管道
    • 各國
  • 市場分析:各國
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章 市場動態

  • 成長要素
  • 課題

第12章 專利(NDA、ANDA)

第13章 市場趨勢

第14章 競爭情形

  • AbbVie Inc
  • Roche Holding AG
  • Novartis International AG
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Merck & Co., Inc
  • Pfizer Inc.
  • Eli Lilly
  • AstraZeneca PLC
  • 武田藥品工業
  • Amgen
  • Astellas Pharma Inc.
  • Sanofi
  • Eisai
  • Abbott
  • Thermo Fisher Scientific
  • Astex Pharmaceutical
  • 第一三共
  • Teva Pharmaceutical

第15章 策略性推薦事項

目錄
Product Code: 4689

Global oncology drugs market is projected to grow at a brisk rate over the forecast period owing to widespread prevalence of cancer, globally. Various other related factors which are contributing to the growth of oncology drugs market include rise in geriatric population worldwide, increase in global healthcare expenditure, rising number of product approvals by regulatory bodies and growing R&D activities for the development of new cancer drugs. Furthermore, emergence of biosimilar products for cancer treatment, increasing collaborations between pharmaceutical companies and development of pipeline oncology products are providing opportunities for various oncology drug manufacturers.

Oncology includes diagnosis, prevention and treatment of cancer diseases. Oncology or anti-cancer drugs can be used alone or in combination to control or destroy neoplastic cells. These drugs have the capacity to treat various kinds of cancers including blood cancer, liver cancer, bone cancer and breast cancer.

However, the oncology drug market also faces some restrains. Fatal effects associated with the use of cancer drugs and high cost of the drug & development process are proving a hindrance for the growth of oncology drugs market.

The global oncology drugs market is segmented based on drug type, therapy, drug therapy, route of administration, gender, cancer type, distribution channel, and region. Based on therapy, the market is segmented into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others. The chemotherapy segment holds the largest market share in global oncology drugs market owing to its ability to kill cancer cells, higher efficacy and higher survival rates. However, the immunotherapy segment is going to witness fastest growth during the forecast period as they do not harm other living cells of the body.

Based on cancer type, the lung cancer segment holds the largest share in the global oncology drugs market due to its considerable surge in prevalence across the world. Major players operating in the global oncology drugs market are AbbVie Inc, Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co., Inc, Pfizer Inc., Eli Lilly, AstraZeneca PLC, Takeda Pharmaceutical, Amgen, Astellas Pharma, Sanofi, Eisai, Abbott, Thermo Fisher Scientific, Astex Pharmaceutical, Daiichi Sankyo, Teva Pharmaceutical and others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global oncology drugs market.
  • To classify and forecast global oncology drugs market based on drug type, therapy, drug therapy, route of administration, gender, cancer type, distribution channel, company and regional distribution.
  • To identify drivers and challenges for global oncology drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global oncology drugs market.
  • To conduct pricing analysis for global oncology drugs market.
  • To identify and analyze the profile of leading players operating in global oncology drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of oncology drug companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. TechSci Research analyzed the presence of all major players across the globe.

TechSci Research calculated the market size of global oncology drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and drug therapies for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Oncology drugs companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to oncology drugs
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global oncology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Drug Type:

Cytotoxic Drugs

Targeted Drugs

Hormonal Drugs

  • Market, By Therapy:

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

  • Market, By Drug Therapy:

Adjuvant

Neoadjuvant

Concurrent

  • Market, By Route of Administration:

Oral

Intravenous

Subcutaneous

Others

  • Market, By Gender:

Male

Female

  • Market, By Cancer Type:

Lung Cancer

Stomach Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Liver Cancer

Esophagus Cancer

Cervical Cancer

Kidney Cancer

Bladder Cancer

Others

  • Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Government Hospitals

  • Market, By Region:

Asia-Pacific

Europe

North America

South America

Middle East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global oncology drugs market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Oncology Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs)
    • 5.2.2. By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others)
    • 5.2.3. By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent)
    • 5.2.4. By Route of Administration (Oral, Intravenous, Subcutaneous, Others)
    • 5.2.5. By Gender (Male, Female)
    • 5.2.6. By Cancer Type (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others)
    • 5.2.7. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Hospitals)
    • 5.2.8. By Company (2019)
    • 5.2.9. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Oncology Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Therapy
    • 6.2.3. By Drug Therapy
    • 6.2.4. By Route of Administration
    • 6.2.5. By Gender
    • 6.2.6. By Cancer Type
    • 6.2.7. By Country
  • 6.3. Asia-Pacific: Country Analysis
    • 6.3.1. China Oncology Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Drug Therapy
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By Gender
        • 6.3.1.2.6. By Cancer Type
    • 6.3.2. India Oncology Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Drug Therapy
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By Gender
        • 6.3.2.2.6. By Cancer Type
    • 6.3.3. Japan Oncology Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Drug Therapy
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By Gender
        • 6.3.3.2.6. By Cancer Type
    • 6.3.4. South Korea Oncology Drugs Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Therapy
        • 6.3.4.2.3. By Drug Therapy
        • 6.3.4.2.4. By Route of Administration
        • 6.3.4.2.5. By Gender
        • 6.3.4.2.6. By Cancer Type
    • 6.3.5. Singapore Oncology Drugs Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Therapy
        • 6.3.5.2.3. By Drug Therapy
        • 6.3.5.2.4. By Route of Administration
        • 6.3.5.2.5. By Gender
        • 6.3.5.2.6. By Cancer Type
    • 6.3.6. Australia Oncology Drugs Market Outlook
      • 6.3.6.1. Market Size & Forecast
        • 6.3.6.1.1. By Value
      • 6.3.6.2. Market Share & Forecast
        • 6.3.6.2.1. By Drug Type
        • 6.3.6.2.2. By Therapy
        • 6.3.6.2.3. By Drug Therapy
        • 6.3.6.2.4. By Route of Administration
        • 6.3.6.2.5. By Gender
        • 6.3.6.2.6. By Cancer Type

7. Europe Oncology Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Therapy
    • 7.2.3. By Drug Therapy
    • 7.2.4. By Route of Administration
    • 7.2.5. By Gender
    • 7.2.6. By Cancer Type
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Oncology Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Drug Therapy
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Gender
        • 7.3.1.2.6. By Cancer Type
    • 7.3.2. Germany Oncology Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Drug Therapy
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Gender
        • 7.3.2.2.6. By Cancer Type
    • 7.3.3. United Kingdom Oncology Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Drug Therapy
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Gender
        • 7.3.3.2.6. By Cancer Type
    • 7.3.4. Italy Oncology Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Drug Therapy
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Gender
        • 7.3.4.2.6. By Cancer Type
    • 7.3.5. Spain Oncology Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Drug Therapy
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Gender
        • 7.3.5.2.6. By Cancer Type

8. North America Oncology Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Therapy
    • 8.2.3. By Drug Therapy
    • 8.2.4. By Route of Administration
    • 8.2.5. By Gender
    • 8.2.6. By Cancer Type
    • 8.2.7. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Oncology Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Drug Therapy
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Gender
        • 8.3.1.2.6. By Cancer Type
    • 8.3.2. Mexico Oncology Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Drug Therapy
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Gender
        • 8.3.2.2.6. By Cancer Type
    • 8.3.3. Canada Oncology Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Drug Therapy
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Gender
        • 8.3.3.2.6. By Cancer Type

9. South America Oncology Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Therapy
    • 9.2.3. By Drug Therapy
    • 9.2.4. By Route of Administration
    • 9.2.5. By Gender
    • 9.2.6. By Cancer Type
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oncology Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Drug Therapy
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Gender
        • 9.3.1.2.6. By Cancer Type
    • 9.3.2. Argentina Oncology Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Drug Therapy
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Gender
        • 9.3.2.2.6. By Cancer Type
    • 9.3.3. Colombia Oncology Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Drug Therapy
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Gender
        • 9.3.3.2.6. By Cancer Type

10. Middle East and Africa Oncology Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Therapy
    • 10.2.3. By Drug Therapy
    • 10.2.4. By Route of Administration
    • 10.2.5. By Gender
    • 10.2.6. By Cancer Type
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oncology Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Drug Therapy
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Gender
        • 10.3.1.2.6. By Cancer Type
    • 10.3.2. Saudi Arabia Oncology Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Drug Therapy
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Gender
        • 10.3.2.2.6. By Cancer Type
    • 10.3.3. UAE Oncology Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Drug Therapy
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Gender
        • 10.3.3.2.6. By Cancer Type
    • 10.3.4. Kuwait Oncology Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Type
        • 10.3.4.2.2. By Therapy
        • 10.3.4.2.3. By Drug Therapy
        • 10.3.4.2.4. By Route of Administration
        • 10.3.4.2.5. By Gender
        • 10.3.4.2.6. By Cancer Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Patents (NDA, ANDA)

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. AbbVie Inc
    • 14.2.2. Roche Holding AG
    • 14.2.3. Novartis International AG
    • 14.2.4. Johnson & Johnson
    • 14.2.5. Bristol-Myers Squibb Company
    • 14.2.6. Celgene Corporation
    • 14.2.7. Merck & Co., Inc
    • 14.2.8. Pfizer Inc.
    • 14.2.9. Eli Lilly
    • 14.2.10. AstraZeneca PLC
    • 14.2.11. Takeda Pharmaceutical
    • 14.2.12. Amgen
    • 14.2.13. Astellas Pharma
    • 14.2.14. Sanofi
    • 14.2.15. Eisai
    • 14.2.16. Abbott
    • 14.2.17. Thermo Fisher Scientific
    • 14.2.18. Astex Pharmaceutical
    • 14.2.19. Daiichi Sankyo
    • 14.2.20. Teva Pharmaceutical

15. Strategic Recommendations

List of Figures

  • Figure 1: Global Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 2: Global Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F
  • Figure 3: Global Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
  • Figure 4: Global Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
  • Figure 5: Global Oncology Drugs Share, By Region (USD Million), 2015-2025F
  • Figure 6: Global Oncology Drugs Share, By Company (USD Million), 2015-2025F
  • Figure 7: Global Oncology Drugs Attractiveness Index, By Region, By Value, 2015-2025F
  • Figure 8: Global Oncology Drugs Attractiveness Index, By Route of Administration Type, By Value, 2015-2025F
  • Figure 9: North America Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 10: North America Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F
  • Figure 11: North America Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
  • Figure 12: North America Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
  • Figure 13: North America Oncology Drugs Share, By Country (USD Million), 2015-2025F
  • Figure 14: North America Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F
  • Figure 15: North America Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 16: United States Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 17: United States Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 18: United States Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 19: United States Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 20: United States Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 21: Canada Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 22: Canada Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 23: Canada Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 24: Canada Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 25: Canada Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 26: Mexico Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 27: Mexico Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 28: Mexico Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 29: Mexico Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 30: Mexico Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 31: Europe Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 32: Europe Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F
  • Figure 33: Europe Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
  • Figure 34: Europe Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
  • Figure 35: Europe Oncology Drugs Share, By Country (USD Million), 2015-2025F
  • Figure 36: Europe Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F
  • Figure 37: Europe Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 38: Russia Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 39: Russia Kingdom Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 40: Russia Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 41: Russia Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 42: Russia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 43: United Kingdom Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 44: United Kingdom Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 45: United Kingdom Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 46: United Kingdom Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 47: United Kingdom Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 48: Italy Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 49: Italy Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 50: Italy Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 51: Italy Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 52: Italy Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 53: Germany Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 54: Germany Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 55: Germany Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 56: Germany Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 57: Germany Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 58: Spain Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 59: Spain Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 60: Spain Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 61: Spain Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 62: Spain Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 63: France Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 64: France Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 65: France Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 66: France Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 67: France Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 68: Asia - Pacific Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 69: Asia - Pacific Oncology Drugs Size, By Drug Type(USD Million), 2015-2025F
  • Figure 70: Asia - Pacific Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
  • Figure 71: Asia - Pacific Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
  • Figure 72: Asia - Pacific Oncology Drugs Share, By Country (USD Million), 2015-2025F
  • Figure 73: Asia - Pacific Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F
  • Figure 74: Asia - Pacific Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 75: China Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 76: China Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 77: China Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 78: China Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 79: China Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 80: China Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 81: India Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 82: India Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 83: India Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 84: India Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 85: India Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 86: Australia Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 87: Australia Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 88: Australia Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 89: Australia Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 90: Australia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 91: Japan Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 92: Japan Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 93: Japan Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 94: Japan Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 95: Japan Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 96: Japan Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 97: Singapore Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 98: Singapore Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 99: Singapore Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 100: Singapore Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 101: Singapore Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 102: South Korea Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 103: South Korea Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 104: South Korea Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 105: South Korea Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 106: South Korea Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 107: South Korea Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 108: Middle East and Africa Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 109: Middle East and Africa Oncology Drugs Size, By Drug Type(USD Million), 2015-2025F
  • Figure 110: Middle East and Africa Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
  • Figure 111: Middle East and Africa Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
  • Figure 112: Middle East and Africa Oncology Drugs Share, By Country (USD Million), 2015-2025F
  • Figure 113: Middle East and Africa Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F
  • Figure 114: Middle East and Africa Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 115: Saudi Arabia Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 116: Saudi Arabia Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 117: Saudi Arabia Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 118: Saudi Arabia Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 119: Saudi Arabia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 120: UAE Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 121: UAE Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 122: UAE Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 123: UAE Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 124: UAE Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 125: UAE Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 126: South Africa Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 127: South Africa Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 128: South Africa Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 129: South Africa Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 130: South Africa Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 131: South Africa Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 132: Kuwait Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 133: Kuwait Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 134: Kuwait Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 135: Kuwait Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 136: Kuwait Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 137: Kuwait Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 138: South America Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 139: South America Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F
  • Figure 140: South America Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
  • Figure 141: South America Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
  • Figure 142: South America Oncology Drugs Share, By Country (USD Million), 2015-2025F
  • Figure 143: South America Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F
  • Figure 144: South America Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 145: Brazil Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 146: Brazil Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 147: Brazil Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 148: Brazil Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 149: Brazil Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 150: Brazil Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 151: Argentina Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 152: Argentina Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 153: Argentina Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 154: Argentina Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 155: Argentina Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
  • Figure 156: Colombia Oncology Drugs Size, By Value (USD Million), 2015-2025F
  • Figure 157: Colombia Oncology Drugs Size, By Drug Type, 2015-2025F
  • Figure 158: Colombia Oncology Drugs Share, By Route of Administration, 2015-2025F
  • Figure 159: Colombia Oncology Drugs Share, By Drug Therapy, 2015-2025F
  • Figure 160: Colombia Oncology Drugs Share, By Strength, 2015-2025F
  • Figure 161: Colombia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F